Pharmacotherapy for patients undergoing carotid stenting

European Journal of Radiology

Volumn 60, Issue 1, 2006, Pages 14-19

  Gopalan, Deepa ^a   Thomas, Steven M ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Carotid stent; Drugs; Medical treatment; Stroke; TIA

Indexed keywords

CAROTID STENTING; ENDOVASCULAR INTERVENTION; TRANSIENT ISCHAEMIC ATTACK (TIA);

CARDIOLOGY; DRUG PRODUCTS; NEUROLOGY; PATIENT TREATMENT; RISK ASSESSMENT; SURGERY;

DRUG THERAPY;

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HEPARIN; SIMVASTATIN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CORONARY STENT; DRUG SAFETY; HUMAN; LIFESTYLE; NEUROLOGIC DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; BLOOD VESSEL PROSTHESIS; CAROTID STENOSIS; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY, ADJUVANT; ENDARTERECTOMY, CAROTID; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PREMEDICATION; STENTS; STROKE; VASODILATOR AGENTS;

EID: 33748777099     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2006.05.024     Document Type: Article

References (60)

1. Murray C.J., and Lopez A.D. Mortality by cause for eight regions of the World: Global Burden of Disease Study. Lancet 349 (1997) 1269-1276
2. De Bakey M.E. Carotid endarterectomy revisited. J Endovasc Surg 3 (1996) 4
3. Coull A.J., Lovett J.K., and Rothwell P.M. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328 (2004) 326
4. Wolfe C.D., Rudd A.G., Howard R., et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry 72 (2002) 211-216
5. Endarterectomy for asymptomatic carotid artery stenosis Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 273 (1995) 1421-1428
6. Wilterdink J.L., and Easton J.D. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 49 (1992) 857-863
7. Guillot F. Atherothrombosis as a marker for disseminated atherosclerosis and a predictor of further ischaemic events. A review. Eur Heart J 1 (1999) A14-A26
8. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
9. Lovett J.K., Dennis M.S., Sandercock P.A., Bamford J., Warlow C.P., and Rothwell P.M. Very early risk of stroke after a first transient ischaemic attack. Stroke 34 (2003) 38-140
10. Peto R. Smoking and death: the past 40 years and the next 40. BMJ 309 (1994) 937-939
11. Hillbom M., Juvela S., and Numminen H. Alcohol intake and the risk of stroke. J Cardiovasc Risk 6 (1999) 223-228
12. Sigal R. Cardiovascular disease in diabetes mellitus. In: Godlee F., Goldmann D., Donald A., and Barton S. (Eds). Clinical evidence, issue 2 (1999), BMJ Publishing Group, London 32-44
13. Wilson P.W., Garrison R.J., and Castelli W.P. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 313 (1985) 1038-1043
14. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., and Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischaemic stroke. N Engl J Med 345 (2001) 1243-1249
15. Patrono C., Ciabattoni G., Patrignani P., et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72 (1985) 1177-1184
16. Taylor D.W., Barnett H.J., Haynes R.B., et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 353 (1999) 2179-2184
17. Reilly I.A., and FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69 (1987) 180-186
18. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39.
19. Hankey G.J., Sudlow C.L., and Dunbabin D.W. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 31 (2000) 1779-1784
20. Diener H.C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
21. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., and Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
22. De Schryver EL, Algra A, van Gijn J, Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2003:CD001820.
23. De Schryver EL. Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group. Cerebrovasc Dis 2000;10:147-50.
24. Garcia Rodriguez L.A., Hernandez-Diaz S., and de Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 52 (2001) 563-571
25. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
26. Norris J.W. Antiplatelet agents in secondary prevention of stroke: a perspective. Stroke 36 (2005) 2034-2036
27. MacMahon S., and Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens Suppl 12 (1994) S5-S14
28. Rothwell P.M., Howard S.C., and Spence J.D. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke 34 (2003) 2583-2590
29. Pekkanen J., Linn S., Heiss G., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 322 (1990) 1700-1707
30. Hebert P.R., Gaziano J.M., Chan K.S., and Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278 (1997) 313-321
31. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
32. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. Am J Cardiol 75 (1995) 1130-1134
33. Collins R., Armitage J., Parish S., Sleight P., and Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
34. Sever P.S., Dahlof B., Poulter N.R., et al. Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. J Hum Hypertens 15 Suppl 1 (2001) S11-S12
35. Plehn J.F., Davis B.R., Sacks F.M., et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99 (1999) 216-223
36. White H.D., Simes R.J., Anderson N.E., et al. Pravastatin therapy and the risk of stroke. N Engl J Med 343 (2000) 317-326
37. Sever P.S., Poulter N.R., Dahlof B., et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 (2005) 1151-1157
38. Liu M, Counsell C, Sandercock P. Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev 2000:CD000248.
39. Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2004:CD000187.
40. Hart R.G., Benavente O., McBride R., and Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131 (1999) 492-501
41. McKevitt F.M., Randall M.S., Cleveland T.J., Gaines P.A., Tan K.T., and Venables G.S. The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg 29 (2005) 522-527
42. Zaman S.M., de Vroos Meiring P., Gandhi M.R., and Gaines P.A. The pharmacokinetics and UK usage of heparin in vascular intervention. Clin Radiol 51 (1996) 113-116
43. Webster S.E., Payne D.A., Jones C.I., et al. Anti-platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy. J Vasc Surg 40 (2004) 463-468
44. Lincoff A.M., Bittl J.A., Kleiman N.S., et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 93 (2004) 1092-1096
45. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
46. Bush R.L., Lin P.H., Mureebe L., Zhou W., Peden E.K., and Lumsden A.B. Routine bivalirudin use in percutaneous carotid interventions. J Endovasc Ther 12 (2005) 521-522
47. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
48. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
49. Kapadia S.R., Bajzer C.T., Ziada K.M., et al. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy. Stroke 32 (2001) 2328-2332
50. Schneiderman J., Morag B., Gerniak A., et al. Abciximab in carotid stenting for postsurgical carotid restenosis: intermediate results. J Endovasc Ther 7 (2000) 263-272
51. Qureshi A.I., Ali Z., Suri M.F., et al. Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement. Neurosurgery 48 (2001) 998-1004
52. Hofmann R., Kerschner K., Steinwender C., Kypta A., Bibl D., and Leisch F. Abciximab bolus injection does not reduce cerebral ischaemic complications of elective carotid artery stenting: a randomized study. Stroke 33 (2002) 725-727
53. Qureshi A.I., Suri M.F., Ali Z., et al. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab. Neurosurgery 50 (2002) 466-473
54. Wholey M.H., Eles G., Toursakissian B., Bailey S., Jarmolowski C., and Tan W.A. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting. J Endovasc Ther 10 (2003) 33-41
55. Ho D.S., Wang Y., Chui M., Ho S.L., and Cheung R.T. Intracarotid abciximab injection to abort impending ischaemic stroke during carotid angioplasty. Cerebrovasc Dis 11 (2001) 300-304
56. Cayne N.S., Faries P.L., Trocciola S.M., et al. Carotid angioplasty and stent-induced bradycardia and hypotension: impact of prophylactic atropine administration and prior carotid endarterectomy. J Vasc Surg 41 (2005) 956-961
57. Howell M., Krajcer Z., Dougherty K., et al. Correlation of periprocedural systolic blood pressure changes with neurological events in high-risk carotid stent patients. J Endovasc Ther 9 (2002) 810-816
58. Morrish W., Grahovac S., Douen A., et al. Intracranial haemorrhage after stenting and angioplasty of extracranial carotid stenosis. Am J Neuroradiol 21 (2000) 1911-1916
59. Pfefferkorn T., Mayer T., Von Stuckrad-Barre S., Covi M., and Hamann G.F. Hyperperfusion-induced intracerebral haemorrhage after carotid stenting documented by TCD. Neurology 57 (2001) 1933-1935
60. Tan K.T., Cleveland T.J., Berczi V., McKevitt F.M., Venables G.S., and Gaines P.A. Timing and frequency of complications after carotid artery stenting: what is the optimal period of observation?. J Vasc Surg 38 (2003) 236-243